Pharmaceutical Mini-Tablets for Flecainide Acetate Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current flecainide acetate controlled release formulations face challenges in achieving consistent and controlled release profiles due to equipment inefficiencies and irregular particle sizes, leading to incomplete coating and variable drug release timing, often resulting in release during transit through the small intestine and colon.
Innovation Solution
A pharmaceutical mini-tablet formulation comprising a core with flecainide acetate, microcrystalline cellulose, and a disintegrant, coated with a pH-dependent release polymer, allowing for sustained release and modified release profiles, reducing local irritation and achieving consistent drug release in the small intestine and colon.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If extrusion-spheronization method is used to prepare flecainide acetate controlled release formulations, then the drug can be released in the small intestine and colon, but the particle size becomes irregular and coating becomes incomplete
Solution Approach 1:
The invention divides the dosage form into multiple mini-tablets (each 2-5mm in diameter) containing controlled amounts of flecainide acetate (5-50mg each). This segmentation allows for more precise manufacturing control compared to large-scale extrusion-spheronization, ensuring uniform size and complete coating while maintaining reliable drug release timing in the small intestine and colon.
Solution Approach 2:
The invention transitions from the traditional extrusion-spheronization process (which operates in one dimension of particle formation) to a mini-tablet compression approach. This dimensional change enables better control over particle geometry, size uniformity, and coating completeness, thereby improving both manufacturing precision and release timing reliability.
2Ease of manufacture
If multiple equipment pieces (kneading machines, extruding machines, spheronizers) are used, then the formulation can be processed, but equipment-related losses increase and yield decreases
Solution Approach 1:
The invention merges multiple processing steps (mixing, granulation, drying, compression) into a streamlined mini-tablet manufacturing process. By consolidating these operations and eliminating the need for separate kneading, extrusion, and spheronization equipment, the process reduces material losses and improves manufacturing yield while maintaining ease of formulation processing.
Solution Approach 2:
The invention extracts and eliminates the problematic extrusion-spheronization step from the manufacturing process. By removing this complex multi-equipment stage and replacing it with direct mini-tablet compression, the process reduces equipment-related losses and improves overall productivity while retaining the necessary formulation processing capabilities.
3Manufacturing precision
If film-coating suspension is applied using fluidized-bed system, then beads can be coated, but excessive coating material is needed to ensure complete coverage, causing irregular release
Solution Approach 1:
The invention applies preliminary action by pre-compressing the mini-tablets to precise dimensions (2-5mm diameter) before coating. This ensures that the subsequent film-coating process requires less material to achieve complete coverage, as the uniform starting geometry allows for more efficient and consistent coating application, thereby maintaining both coating completeness and release standardization.
4Reliability
If flecainide acetate concentration is increased in modified release composition, then the composition becomes more efficacious, but the release profile becomes harder to control
Solution Approach 1:
The invention segments the total flecainide acetate dose into multiple mini-tablets, each containing a controlled amount of the active ingredient (5-50mg). This segmentation allows for higher overall concentrations while maintaining consistent release profiles, as each individual mini-tablet can be precisely manufactured and coated, ensuring uniform drug release across the entire dosage form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mini-tablet formulation provides a consistent and prolonged release of flecainide acetate, maintaining therapeutic levels for extended periods, enabling once or twice daily dosing and effective treatment of cardiac arrhythmias with reduced equipment-related losses and improved yield.
Implementation Method 1
an outer cover layer including a pH-dependent release polymer
Data Source
Figure 1
AI summary
The invention relates to a pharmaceutical mini-tablet for sustained release of flecainide acetate which exhibits a different sustained profile, comprising a core including flecainide acetate, microcrystalline cellulose, and a disintegrant, and an outer cover layer including a pH- dependent release polymer and excipients. Also relates to a process for the preparation of said mini-tablet which comprises a) blending flecainide acetate with microcrystalline cellulose and disintegrant to obtain a blended mixture; b) granulating the blended mixture with an aqueous solution of a binder; c) drying the obtained granulate; d) lubricating, when present, the dried granules and compressing it to obtain the core; and e) preparing an aqueous dispersion which comprises the pH- dependent polymer with excipients and coating the core to obtain the outer cover layer. Thus, it provides an efficacious sustained release of flecainide acetate in a pharmaceutical form for oral administration in the treatment of cardiac arrhythmias.